Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Andes

Showing results (31-40 of 207) with videos related to

Pageof 21
Sort By:
Medical Mycology|May 5, 2011
Comparative analysis of Candida biofilm quantitation assaysHeather T Taff, Jeniel E Nett, David R Andes
Cold Spring Harbor Perspectives in Medicine|October 3, 2014
Fungal biofilms, drug resistance, and recurrent infectionJigar V Desai, Aaron P Mitchell, David R Andes
Biomacromolecules|May 14, 2003
Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activityMonica L Adams, David R Andes, Glen S Kwon
Antimicrobial Agents and Chemotherapy|October 9, 2013
Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatusAlexander J Lepak, Karen Marchillo, Jamie Vanhecker, et al.
Antimicrobial Agents and Chemotherapy|November 14, 2012
Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosisAlexander J Lepak, Karen Marchillo, Jaimie Vanhecker, et al.
Expert Opinion on Drug Delivery|December 14, 2025
The use of nanocarriers for the treatment of <i>Candida auris</i> infectionsAnna Jaromin, Robert Zarnowski, David R Andes, et al.
Antimicrobial Agents and Chemotherapy|July 24, 2019
<i>In Vivo</i> Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia ModelMiao Zhao, Alexander J Lepak, Karen Marchillo, et al.
Antimicrobial Agents and Chemotherapy|June 3, 2010
Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyeneJeniel E Nett, Kyler Crawford, Karen Marchillo, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2013
Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolatesAlexander J Lepak, Karen Marchillo, Jamie VanHecker, et al.
Infection and Immunity|July 8, 2010
Development and validation of an in vivo Candida albicans biofilm denture modelJeniel E Nett, Karen Marchillo, Carol A Spiegel, et al.
Pageof 21

Showing results (31-40 of 207) with videos related to

Sort By:
Pageof 21
Medical Mycology|May 5, 2011
Comparative analysis of Candida biofilm quantitation assaysHeather T Taff, Jeniel E Nett, David R Andes
Cold Spring Harbor Perspectives in Medicine|October 3, 2014
Fungal biofilms, drug resistance, and recurrent infectionJigar V Desai, Aaron P Mitchell, David R Andes
Biomacromolecules|May 14, 2003
Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activityMonica L Adams, David R Andes, Glen S Kwon
Antimicrobial Agents and Chemotherapy|October 9, 2013
Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatusAlexander J Lepak, Karen Marchillo, Jamie Vanhecker, et al.
Antimicrobial Agents and Chemotherapy|November 14, 2012
Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosisAlexander J Lepak, Karen Marchillo, Jaimie Vanhecker, et al.
Expert Opinion on Drug Delivery|December 14, 2025
The use of nanocarriers for the treatment of <i>Candida auris</i> infectionsAnna Jaromin, Robert Zarnowski, David R Andes, et al.
Antimicrobial Agents and Chemotherapy|July 24, 2019
<i>In Vivo</i> Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia ModelMiao Zhao, Alexander J Lepak, Karen Marchillo, et al.
Antimicrobial Agents and Chemotherapy|June 3, 2010
Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyeneJeniel E Nett, Kyler Crawford, Karen Marchillo, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2013
Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolatesAlexander J Lepak, Karen Marchillo, Jamie VanHecker, et al.
Infection and Immunity|July 8, 2010
Development and validation of an in vivo Candida albicans biofilm denture modelJeniel E Nett, Karen Marchillo, Carol A Spiegel, et al.
Pageof 21